MAPT and Alzheimer disease: A recent study found blood levels of phosphorylated tau (p-tau)231 and p-tau217 could detect early cerebral Aβ pathologies demonstrating their importance as biomarkers for preclinical AD (Milà-Alomà et al., 2022).